Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

被引：0
|
作者：
Sheila Seleri Assunção
Reisa A. Sperling
Craig Ritchie
Diana R. Kerwin
Paul S. Aisen
Claire Lansdall
Alireza Atri
Jeffrey Cummings
机构：
[1] US Medical Affairs – Neuroscience,Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences
[2] Genentech,Department of Neurology and Neurotherapeutics
[3] A Member of the Roche Group,Center for Brain/Mind Medicine, Department of Neurology
[4] Brigham and Women’s Hospital,Chambers
[5] Massachusetts General Hospital,Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences
[6] Harvard Medical School,undefined
[7] University of Edinburgh,undefined
[8] Kerwin Medical Center,undefined
[9] University of Texas Southwestern Medical Center,undefined
[10] University of Southern California Alzheimer’s Therapeutic Research Institute,undefined
[11] F. Hoffmann-La Roche,undefined
[12] Banner Sun Health Research Institute,undefined
[13] Brigham and Women’s Hospital,undefined
[14] Harvard Medical School,undefined
[15] University of Nevada,undefined
来源：
Alzheimer's Research & Therapy | / 14卷
关键词：
Alzheimer’s disease; Clinical trials; Clinical meaningfulness; Meaningful benefit; Biomarkers; Preclinical; Mild cognitive impairment due to Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease
    Assuncao, Sheila Seleri
    Sperling, Reisa A.
    Ritchie, Craig
    Kerwin, Diana R.
    Aisen, Paul S.
    Lansdall, Claire
    Atri, Alireza
    Cummings, Jeffrey
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [2] Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease
    Scorer, CA
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (23) : 1207 - 1219
  • [3] Disease-modifying therapies in Alzheimer's disease
    Salloway, Stephen
    Mintzer, Jacobo
    Weiner, Myron F.
    Cummings, Jeffrey L.
    [J]. ALZHEIMERS & DEMENTIA, 2008, 4 (02) : 65 - 79
  • [4] Novel Disease-Modifying Therapies for Alzheimer's Disease
    Jiang, Teng
    Yu, Jin-Tai
    Tan, Lan
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2012, 31 (03) : 475 - 492
  • [5] Disease-modifying therapies for Alzheimer disease
    Cummings, Jeffrey L.
    Doody, Rachelle
    Clark, Christopher
    [J]. NEUROLOGY, 2007, 69 (16) : 1622 - 1634
  • [6] Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease
    Munoz-Torrero, D.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2008, 15 (24) : 2433 - 2455
  • [7] Development of disease-modifying therapies against Alzheimer's disease
    Iwatsubo, Takeshi
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2024, 78 (09) : 491 - 494
  • [8] Insight Preparing for disease-modifying therapies in Alzheimer's disease
    Belder, Christopher R. S.
    Schott, Jonathan M.
    Fox, Nick C.
    [J]. LANCET NEUROLOGY, 2023, 22 (09): : 782 - 783
  • [9] Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease
    Apter, Jeffrey T.
    Shastri, Kuntal
    Pizano, Katherine
    [J]. CURRENT GERIATRICS REPORTS, 2015, 4 (04): : 312 - 317
  • [10] The past, present, and future of disease-modifying therapies for Alzheimer's disease
    Suzuki, Kazushi
    Iwata, Atsushi
    Iwatsubo, Takeshi
    [J]. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2017, 93 (10): : 757 - 771
12345